Ep-CAM is a significant prognostic factor in pancreatic cancer patients by suppressing cell activity (Q39576941)

13 September 2017

Ep-CAM is a significant prognostic factor in pancreatic cancer patients by suppressing cell activity (English)

1 reference

13 September 2017

1 reference

H Akita

1

1 reference

13 September 2017

H Nagano

2

1 reference

13 September 2017

Y Takeda

3

1 reference

13 September 2017

H Eguchi

4

1 reference

13 September 2017

H Wada

5

1 reference

13 September 2017

S Kobayashi

6

1 reference

13 September 2017

S Marubashi

7

1 reference

13 September 2017

M Tanemura

8

1 reference

13 September 2017

H Takahashi

9

1 reference

13 September 2017

H Ohigashi

10

1 reference

13 September 2017

Y Tomita

11

1 reference

13 September 2017

O Ishikawa

12

1 reference

13 September 2017

M Mori

13

1 reference

13 September 2017

Y Doki

14

1 reference

13 September 2017

language of work or name

English

0 references

publication date

14 March 2011

1 reference

13 September 2017

1 reference

13 September 2017

30

1 reference

13 September 2017

31

1 reference

13 September 2017

3468-3476

1 reference

https://scigraph.springernature.com/pub.10.1038/onc.2011.59

13 September 2017

0 references

cites work

EpCAM: A New Therapeutic Target for an Old Cancer Antigen

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.59

The structural analysis of adhesions mediated by Ep-CAM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.59

The biology of the 17-1A antigen (Ep-CAM)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.59

Assignment of TACSTD1 (alias TROP1, M4S1) to human chromosome 2p21 and refinement of mapping of TACSTD2 (alias TROP2, M1S1) to human chromosome 1p32 by in situ hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.59

KSA antigen Ep-CAM mediates cell-cell adhesion of pancreatic epithelial cells: morphoregulatory roles in pancreatic islet development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.59

Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.59

Ep-CAM expression in pancreatic and ampullary carcinomas: frequency and prognostic relevance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.59

Prognostic indicators for survival after resection of pancreatic adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.59

EpCAM is involved in maintenance of the murine embryonic stem cell phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.59

Cell adhesion: the molecular basis of tissue architecture and morphogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.59

Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.59

Identification of pancreatic cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.59

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.59

Epithelial cell adhesion molecule (Ep-CAM) modulates cell-cell interactions mediated by classic cadherins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.59

Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.59

The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.59

Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.59

Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.59

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.59

Hepatic expression of ANG2 RNA in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.59

EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.59

Transcriptional repression of epithelial cell adhesion molecule contributes to p53 control of breast cancer invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.59

Prognostic effect of epithelial cell adhesion molecule overexpression in untreated node-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.59

Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.59

Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.59

Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.59

Loss of Ep-CAM (CO17-1A) expression predicts survival in patients with gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.59

Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.59

Ep-CAM expression in squamous cell carcinoma of the esophagus: a potential therapeutic target and prognostic marker

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.59

DNA methylation and histone modification regulate silencing of epithelial cell adhesion molecule for tumor invasion and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.59

Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.59

Thiazolidinediones inhibit growth of gastrointestinal, biliary, and pancreatic adenocarcinoma cells through activation of the peroxisome proliferator-activated receptor gamma/retinoid X receptor alpha pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.59

Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.59

The epithelial cell adhesion molecule (Ep-CAM) as a morphoregulatory molecule is a tool in surgical pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.59

EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.59

Colorectal carcinoma invasion inhibition by CO17-1A/GA733 antigen and its murine homologue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.59

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.59

Ep-CAM overexpression in breast cancer as a predictor of survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.59

Loss of membranous Ep-CAM in budding colorectal carcinoma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.59

Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.59

Epithelial glycoprotein-2 expression is subject to regulatory processes in epithelial-mesenchymal transitions during metastases: an investigation of human cancers transplanted into severe combined immunodeficient mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.59

An evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.59

Isolation and characterization of a carcinoma-associated antigen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.59

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.59

31 March 2020

Identifiers

DOI

10.1038/ONC.2011.59

1 reference

13 September 2017

1 reference